Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2650300 | 0.87 | ALDH1A1 (0.44) | ALDH1A1KDM4ENPC1RAB9AMAPT | |
| SCHEMBL2658954 | 0.82 | GABRG2 (0.41) | ALDH1A1KMT2ASMN1; SMN2GABRA1GABRG2 | |
| SCHEMBL2649439 | 0.81 | GABRG2 (0.44) | ALDH1A1KDM4EGABRA1GABRG2GABRB3 | |
| SCHEMBL2646665 | 0.80 | GABRG2 (0.41) | ALDH1A1KDM4ENPC1RAB9AMAPT | |
| SCHEMBL2650206 | 0.79 | ALDH1A1 (0.43) | ALDH1A1KDM4ENPC1RAB9AMAPT | |
| SCHEMBL7079058 | 0.78 | GABRG2 (0.52) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11282512 | 0.76 | KDM4E (0.49) | ALDH1A1KDM4ENPC1RAB9AMAPT | |
| SCHEMBL11279115 | 0.74 | ALDH1A1 (0.46) | ALDH1A1KDM4ENPC1RAB9AMAPT | |
| SCHEMBL2657570 | 0.71 | GABRG2 (0.53) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL7237121 | 0.70 | GABRA1 (0.44) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6541484-B2 | Central nervous system disorders; psychological disorders | MERCK SHARP & DOHME LIMITED | 2003-04-01 | — | — | US | claimed |
| US-20030004180-A1 | Pyrazolo-pyridine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2003-01-02 | — | — | US | claimed |
| EP-1244659-A1 | PYRAZOLO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2002-10-02 | — | — | EP | claimed |
| WO-2001044244-A1 | PYRAZOLO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2001-06-21 | — | — | WO | claimed |
| US-6541484-B2 | Central nervous system disorders; psychological disorders | MERCK SHARP & DOHME LIMITED | 2003-04-01 | — | — | US | disclosed |
| US-20030004180-A1 | Pyrazolo-pyridine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004180-A1 | Pyrazolo-pyridine derivatives as ligands for gaba receptors | GABRA3, GABRA4, GABRB3 | ALDH1A1 1355/4885KDM4E 2289/4885NPC1 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.